HSETD1A regulates wnt target genes and controls tumor growth of colorectal cancer cells

Cancer Research

Volumn 74, Issue 3, 2014, Pages 775-786

  Salz, Tal ^a   Li, Guangyao ^b   Kaye, Frederic ^a,b   Zhou, Lei ^a,b   Qiu, Yi ^a,b   Huang, Suming ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; MICE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR BURDEN; WNT PROTEINS; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893824155     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1400     Document Type: Article

References (34)

1. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007; 39:311-8.
2. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 2007;25:15-30.
3. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010;10:721-8.
4. Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem 2012;81:65-95.
5. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE,WangZ, et al. Highresolution profiling of histone methylations in the human genome. Cell 2007;129:823-37.
6. Morgan MA, Shilatifard A. Drosophila SETs its Sights on Cancer: Trr/ MLL3/4 COMPASS-like complexes in Development and Disease. Mol Cell Biol 2013;33:1698-701.
7. Deng C, Li Y, Liang S, Cui K, Salz T, Yang H, et al. USF1 and hSET1A mediated epigenetic modifications regulate lineage differentiation and HoxB4 transcription. PLoS Genet 2013;9: e1003524.
8. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
9. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013;339:1567-70.
10. Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, Balasubramanian D, et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science 2012;336: 736-9.
11. Enroth S, Rada-Iglesisas A, Andersson R, Wallerman O, Wanders A, Pahlman L, et al. Cancer associated epigenetic transitions identified by genome-wide histone methylation binding profiles in human colorectal cancer samples and paired normal mucosa. BMC Cancer 2011; 11:450.
12. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol 2011;18:867-74.
13. Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC, et al. Interplay between HDAC3 and WDR5 is essential for hypoxiainduced epithelial-mesenchymal transition. Mol Cell 2011;43: 811-22.
14. Ke XS, Qu Y, Cheng Y, Li WC, Rotter V, Oyan AM, et al. Global profiling of histone andDNAmethylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomics 2010;11:669.
15. Li Q, Shi L, Gui B, Yu W, Wang J, Zhang D, et al. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res 2011;71:6899-908.
16. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009;138:660-72.
17. Arzate-Mejia RG, Valle-Garcia D, Recillas-Targa F. Signaling epigenetics: novel insights on cell signaling and epigenetic regulation. IUBMB Life 2011;63:881-95.
18. Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I, et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012;336:1549-54.
19. Cadigan KM, Peifer M. Wnt signaling from development to disease: insights from model systems. Cold Spring Harb Perspect Biol 2009;1: a002881.
20. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
21. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007;17:45-51.
22. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-11.
23. Hirata A, Utikal J,Yamashita S, Aoki H, Watanabe A, Yamamoto T, et al. Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium. Development 2013;140:66-75.
24. Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 2006;7:349-59.
25. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111:241-50.
26. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24.
27. Suraweera N, Robinson J, Volikos E, Guenther T, Talbot I, Tomlinson I, et al. Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines. Int J Cancer 2006;119:1837-42.
28. Li X, Wang S, Li Y, Deng C, Steiner LA, Xiao H, et al. Chromatin boundaries require functional collaboration between the hSET1 and NURF complexes. Blood 2011;118:1386-94.
29. Lemieux S. Probe-level linear model fitting and mixture modeling results in high accuracy detection of differential gene expression.BMC Bioinformatics 2006;7:391.
30. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005;21:2067-75.
31. Lauberth SM, Nakayama T, Wu X, Ferris AL, Tang Z, Hughes SH, et al. H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation. Cell 2013;152:1021-36.
32. Sierra J, Yoshida T, Joazeiro CA, Jones KA. TheAPCtumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 2006;20:586-600.
33. Teo JL, Kahn M. The Wnt signaling pathway in cellular proliferation and differentiation: a tale of two coactivators. Adv Drug Deliv Rev 2010;62:1149-55.
34. van Ingen H, van Schaik FM, Wienk H, Ballering J, Rehmann H, Dechesne AC, et al. Structural insight into the recognition of the H3K4me3 mark by the TFIID subunit TAF3. Structure 2008;16: 1245-56.